» Articles » PMID: 36404388

Evaluation of Neonatal and Paediatric Vancomycin Pharmacokinetic Models and the Impact of Maturation and Serum Creatinine Covariates in a Large Multicentre Data Set

Overview
Specialty Pharmacology
Date 2022 Nov 20
PMID 36404388
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: Infants and neonates present a clinical challenge for dosing drugs with high interindividual variability due to these patients' rapid growth and the interplay between maturation and organ function. Model-informed precision dosing (MIPD), which can account for interindividual variability via patient characteristics and Bayesian forecasting, promises to improve individualized dosing strategies in this complex population. Here, we assess the predictive performance of published population pharmacokinetic models describing vancomycin in neonates and infants, and analyze the robustness of these models in the face of clinical uncertainty surrounding covariate values.

Methods: The predictive precision and bias of nine pharmacokinetic models were compared in a large multi-site data set (N = 2061 patients, 5794 drug levels, 28 institutions) of patients aged 0-365 days. The robustness of model predictions to errors in serum creatinine measurements and gestational age was assessed by using recorded values or by replacing covariate values with 0.3, 0.5 or 0.8 mg/dL or with 40 weeks, respectively.

Results: Of the nine models, two models (Dao and Jacqz-Aigrain) resulted in predicted concentrations within 2.5 mg/L or 15% of the measured values for at least 60% of population predictions. Within individual models, predictive performance often 2 differed in neonates (0-4 weeks) versus older infants (15-52 weeks). For preterm neonates, imputing gestational age as 40 weeks reduced the accuracy of model predictions. Measured values of serum creatinine improved model predictions compared to using imputed values even in neonates ≤1 week of age.

Conclusions: Several available pharmacokinetic models are suitable for MIPD in infants and neonates. Availability and accuracy of model covariates for patients will be important for guiding dose decision-making.

Citing Articles

External evaluation of neonatal vancomycin population pharmacokinetic models: Moving from first-order equations to Bayesian-guided therapeutic monitoring.

Blouin M, Metras M, Gaudreault C, Dube M, Boulanger M, Cloutier K Pharmacotherapy. 2024; 44(12):907-919.

PMID: 39544156 PMC: 11687215. DOI: 10.1002/phar.4623.


Comparison of Vancomycin AUC24 Calculation Methods for Neonates and Infants.

Laitila T, Sankilampi U, Renko M, Kokki M, Ranta V Eur J Drug Metab Pharmacokinet. 2024; 49(6):773-779.

PMID: 39438393 PMC: 11549144. DOI: 10.1007/s13318-024-00920-5.


Developing Parametric and Nonparametric Models for Model-Informed Precision Dosing: A Quality Improvement Effort in Vancomycin for Patients With Obesity.

Hughes M, Hughes J, Endicott J, Langton M, Ahern J, Keizer R Ther Drug Monit. 2024; 46(5):575-583.

PMID: 38758633 PMC: 11389886. DOI: 10.1097/FTD.0000000000001214.


Does Sample Size, Sampling Strategy, or Handling of Concentrations Below the Lower Limit of Quantification Matter When Externally Evaluating Population Pharmacokinetic Models?.

El Hassani M, Liebchen U, Marsot A Eur J Drug Metab Pharmacokinet. 2024; 49(4):419-436.

PMID: 38705941 DOI: 10.1007/s13318-024-00897-1.


Comment on: "External Evaluation of Population Pharmacokinetic Models for Precision Dosing: Current State and Knowledge Gaps".

Lv M, Zhang S Clin Pharmacokinet. 2023; 62(8):1183-1185.

PMID: 37351794 DOI: 10.1007/s40262-023-01271-1.


References
1.
Allegaert K, van den Anker J . Neonates are not just little children and need more finesse in dosing of antibiotics. Acta Clin Belg. 2018; 74(3):157-163. DOI: 10.1080/17843286.2018.1473094. View

2.
Anderson B, Holford N . Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2007; 48:303-32. DOI: 10.1146/annurev.pharmtox.48.113006.094708. View

3.
Tong D, Hughes J, Keizer R . Use of Age-Adjusted Serum Creatinine in a Vancomycin Pharmacokinetic Model Decreases Predictive Performance in Elderly Patients. Ther Drug Monit. 2020; 43(1):139-140. DOI: 10.1097/FTD.0000000000000819. View

4.
Lu H, Rosenbaum S . Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2015; 19(4):262-76. PMC: 4341411. DOI: 10.5863/1551-6776-19.4.262. View

5.
Eberg M, Platt R, Filion K . The Estimation of Gestational Age at Birth in Database Studies. Epidemiology. 2017; 28(6):854-862. DOI: 10.1097/EDE.0000000000000713. View